BIOMEX develops unique SARS-CoV-2 immunity seroconversion panels

Does your anti-SARS-CoV-2 assay detect antibodies formed after vaccination? And will your anti-SARS-CoV-2 assay allow quantitative detection of antibody concentration to evaluate vaccination success?

To support the IvD & pharma industries in their efforts against the COVID-19 pandemic, unique SARS-CoV-2 immunity seroconversion panels are now being developed by BIOMEX.

These post vaccination panels consist of a collection of donors immunized with either BioNTech/Pfizer or Moderna vaccine.

We are currently collecting the following sample set:
The existing panel consists of 16 donations from 50 donors containing 1 mL of serum from each member.
The collection period expands over 8 weeks with 2 donations per week.
Accordingly, this seroconversion panel will have a total size of 800 serum samples.
The first collections have started at the first vaccination.

You can receive the vaccination panel at the end of the collection or as partial shipments.

Please contact to determine the appropriate panel size for your customized requirements.

This site is registered on as a development site.